

1 **Change in Plasma Alpha-Tocopherol Associations with Attenuated Pulmonary Function**  
2 **Decline and with *CYP4F2* Missense Variation**

3  
4 Jiayi Xu<sup>1,2</sup>, Kristin A. Guertin<sup>1,3</sup>, Nathan C. Gaddis<sup>4</sup>, Anne H. Agler<sup>1,5</sup>, Robert S. Parker<sup>1</sup>,  
5 Jared M. Feldman<sup>1</sup>, Alan R. Kristal<sup>6,7</sup>, Kathryn B. Arnold<sup>8</sup>, Phyllis J. Goodman<sup>8</sup>, Catherine M.  
6 Tangen<sup>6</sup>, Dana B. Hancock<sup>4</sup>, and Patricia A. Cassano<sup>1,9</sup>

7  
8 <sup>1</sup> Division of Nutritional Sciences, Cornell University, Ithaca, NY

9 <sup>2</sup> Pamela Sklar Division of Psychiatric Genomics, Icahn School of Medicine at Mount Sinai,  
10 New York, NY

11 <sup>3</sup> Department of Public Health Sciences, University of Virginia School of Medicine,  
12 Charlottesville, VA

13 <sup>4</sup> GenOmics, Bioinformatics, and Translational Research Center, Biostatistics and Epidemiology  
14 Division, RTI International, Research Triangle Park, NC

15 <sup>5</sup> Abbott, Columbus, OH

16 <sup>6</sup> Fred Hutchinson Cancer Research Center, Seattle, WA

17 <sup>7</sup> Department of Epidemiology, University of Washington, Seattle, WA

18 <sup>8</sup> SWOG Statistical Center, Seattle, WA

19 <sup>9</sup> Department of Population Health Sciences, Division of Epidemiology, Weill Cornell Medical  
20 College, New York, NY

21  
22 **Corresponding author:**

23 Patricia A. Cassano, PhD

24 Division of Nutritional Sciences, Cornell University

25 209 Savage Hall

26 Cornell University

27 Ithaca, NY 14853

28 [pac6@cornell.edu](mailto:pac6@cornell.edu)

29 607 255 7551 (ph); 607 255 2691 (fax)

30 **Abstract**

31 *Background:* Given its antioxidant activity, vitamin E is hypothesized to attenuate the age-related  
32 decline in pulmonary function.

33 *Objective:* We investigated the association between change in plasma vitamin E ( $\Delta$ vitE) and  
34 pulmonary function decline and examined genetic and non-genetic factors associated with  $\Delta$ vitE.

35 *Design:* We studied 1,144 men randomized to vitE in the Selenium and Vitamin E Cancer  
36 Prevention Trial.  $\Delta$ vitE was calculated as the difference between baseline and year 3 vitE  
37 concentrations measured with gas chromatography-mass spectrometry. Pulmonary function  
38 (forced expiratory volume in the first second [FEV<sub>1</sub>]) was measured longitudinally with  
39 spirometry. We genotyped 555 participants (vitE-only arm) using the Illumina MEGA<sup>ex</sup> array.  
40 We examined the association of  $\Delta$ vitE with annual change in FEV<sub>1</sub> using mixed-effects linear  
41 regression. We also examined the association of previously reported genetic and non-genetic  
42 factors with  $\Delta$ vitE.

43 *Results:* Greater  $\Delta$ vitE was associated with attenuated FEV<sub>1</sub> decline, with stronger effects in  
44 adherent supplement responders: a 1 SD *higher*  $\Delta$ vitE (+4  $\mu$ mol/mmol free-cholesterol-adjusted  
45  $\alpha$ -tocopherol) attenuated FEV<sub>1</sub> decline by ~8.9 mL/year ( $P=0.014$ ). This effect size is ~¼ of the  
46 effect of one year of aging, but in the opposite direction. The  $\Delta$ vitE-FEV<sub>1</sub> association was  
47 positive in never and current smokers (9.7 and 11.0 mL/year attenuated FEV<sub>1</sub> decline,  
48 respectively), but there was little to no association in former smokers. *Greater*  $\Delta$ vitE was  
49 associated with *lower* baseline  $\alpha$ -tocopherol, *higher* baseline  $\gamma$ -tocopherol, *higher* baseline free  
50 cholesterol, European ancestry (vs. African ancestry) (all  $P<0.0001$ ), and the minor allele of a  
51 missense variant in *CYP4F2* (rs2108622-T) (2.4  $\mu$ mol/L *greater*  $\Delta$ vitE;  $P=0.0032$ ).

52 *Conclusions:* Greater response to vitE supplementation was associated with attenuated FEV<sub>1</sub>  
53 decline, and this response was differed by rs2108622 such that individuals with the *C* allele may  
54 need a higher vitE intake dose to reach the same plasma level, compared to the *T* allele.

55

56 *Keywords:* vitamin E, pulmonary function tests, *CYP4F2*, human, male, clinical trial, smoking,  
57 continental population groups, genome-wide association study

## 58 ***Introduction***

59           Vitamin E (vitE) is posited to have beneficial effects on lung health, given its role as a  
60 lipid-soluble antioxidant nutrient that scavenges free radicals in cells that can otherwise damage  
61 lung and other tissues (1, 2). Among the 8 forms of vitE, alpha-tocopherol ( $\alpha$ -TOH) is the most  
62 abundant form in the circulation due to preferential post-absorption retention, while gamma-  
63 tocopherol ( $\gamma$ -TOH) is the major form in the U.S. diet (e.g., rich in vegetable oil and nuts).  
64 Positive association of vitE with cross-sectional pulmonary function (i.e., measured at a single  
65 time point) are reported in some (3-15), but not all (6, 11, 16-23) studies. Only two studies  
66 investigated associations with longitudinal decline in pulmonary function; a study of dietary  
67 intake of vitE with pulmonary function reported little to no association (4), while a study of  
68 serum vitE reported an association of lower baseline vitE with steeper decline in pulmonary  
69 function in heavy smokers (24). To our knowledge, the Respiratory Ancillary Study (RAS) to the  
70 Selenium and Vitamin E Cancer Prevention Trial (SELECT) is the only randomized controlled  
71 trial (RCT) to investigate the effect of vitE supplementation on pulmonary function decline. The  
72 RAS studied 2,920 men and, in an intention-to-treat analysis, reported a non-statistically  
73 significant ( $P = 0.19$ ) protective effect of supplementation on decline (-33 mL/year in the vitE  
74 arm *versus* -39 mL/year in the placebo arm), but no evidence for an interaction of vitE  
75 supplementation with smoking status (25).

76           RCTs provide high-quality evidence to infer causal effects of nutrition on chronic disease  
77 outcomes, but intention-to-treat analyses have often failed to confirm nutrient-disease  
78 associations reported in observational studies and/or animal studies (26-28). While the RCT  
79 intention-to-treat design preserves randomization and a balance in participant characteristics by  
80 study arm (29), the intention-to-treat analysis may limit inferences for nutrition interventions if

81 the intervention effect varies by individual characteristics including baseline nutriture and  
82 genetic variation. Thus, the efficacy of nutrient supplementation might vary by population  
83 subgroups, which would inform a precision nutrition approach, analogous to the concept of  
84 precision medicine (30).

85 An *in silico* simulation study reported that genes related to vitE metabolism are highly  
86 polymorphic (31) making it plausible that genetic differences contribute to inter-individual  
87 variation in response to supplementation. Genome-wide association studies (GWAS) have  
88 identified several genetic variants associated with cross-sectional plasma vitE concentration (32-  
89 34), and one study in men who were lifelong heavy smokers reported 2 genome-wide significant  
90 variants associated with plasma  $\alpha$ -TOH concentration after 3 years of vitE supplementation (35).

91 We investigated the association of change in plasma vitE level (hereafter,  $\Delta$ vitE), as a  
92 biomarker for the response to intervention with a supplement, with age-related decline in  
93 pulmonary function. We hypothesized that a greater response to vitE supplementation would  
94 lead to an attenuated pulmonary function decline in a generally healthy male population and  
95 tested this hypothesis in the RAS using a dose-response analysis. Furthermore, we hypothesized  
96 that genetic and non-genetic factors contribute to inter-individual differences in  $\Delta$ vitE leading to  
97 sub-populations that benefit differentially from the same level of vitE supplementation.

98

## 99 ***Methods***

### 100 *Study Design and Participants*

101 This study uses data from the RAS to SELECT, which was a phase 3 randomized  
102 controlled double-blinded trial of vitamin E and/or selenium supplementation for prostate cancer  
103 prevention. Details of the RAS and SELECT are published elsewhere (25, 36). Briefly, SELECT

104 recruited 35,533 men aged  $\geq 50$  years for African Americans or  $> 55$  years for all other men in  
105 the United States, Canada, and Puerto Rico. Eligibility criteria for SELECT included no prostate  
106 cancer diagnosis or suspicion of cancer, a serum prostate-specific antigen concentration  $\leq 4$   
107 ng/mL, no more than 175 mg/day acetylsalicylic acid or 81 mg/day of acetylsalicylic acid if  
108 combined with clopidogrel bisulfate for anticoagulant therapy, a normal blood pressure, and no  
109 history of hemorrhagic stroke (36).

110 The RAS included men from 16 SELECT sites and preserved the randomized design. The  
111 four study arms were: vitE [400 IU/day of synthetic *all rac*- $\alpha$ -tocopheryl acetate] + selenium  
112 (Se) [200  $\mu$ g/day of L-selenomethionine] (vitE+Se arm); vitE + Se placebo (vitE arm); vitE  
113 placebo + Se (Se arm); and vitE placebo + Se placebo (double placebo arm). The safety and  
114 efficacy of the supplementation have been considered in the original SELECT Trial (26). The  
115 primary endpoint of RAS was annual decline in FEV<sub>1</sub>; the secondary endpoint was annual  
116 decline in FEF<sub>25-75</sub>. These endpoints did not change significantly during the course of study  
117 across the intervention arms (25), which led us to the current exploratory analysis using the  
118 biomarker change as the exposure, instead of studying the effects of the intervention arms. The  
119 Cornell University IRB and the IRB at each of the 16 study sites approved the study. Analyses in  
120 this study focused on 1,144 participants of European or African ancestry in the two vitE (vitE or  
121 vitE+Se) arms with baseline (pre-intervention) and year 3 (on intervention) plasma vitE blood  
122 samples and at least 1 pulmonary function measurement (**Figure 1**).

### 123 Pulmonary Function

124 Pulmonary function, including forced expiratory volume in the first second (FEV<sub>1</sub>), was  
125 measured via the EasyOne handheld spirometer, which was previously tested for validity and  
126 reliability (37). The primary endpoint in the RAS was annual rate of change in FEV<sub>1</sub>. Pulmonary

127 function tests (PFTs) were performed at specified SELECT visits in the RAS participants. Only  
128 PFTs meeting ATS standardization criteria (38) were included, and repeated PFTs had to be at  
129 least 2 years apart (from the first to the last PFT measure) to be included in our analyses.

### 130 Vitamin E

131 Plasma vitE was assayed in samples from men in the vitE arms of the study and in a  
132 random sample of men in the double placebo arm. Blood samples were collected at SELECT  
133 baseline (prior to the start of supplements) and at the year 3 annual visit and stored at -80°C for a  
134 maximum of 9 years (see **Supplemental Methods**). Plasma  $\alpha$ -TOH,  $\gamma$ -TOH and free un-  
135 esterified cholesterol were assayed via gas chromatography-mass spectrometry (GC-MS) on a  
136 Hewlett Packard 6890 gas chromatograph coupled with a Hewlett Packard 6890 mass  
137 spectrometer (Palo Alto, CA). Free cholesterol was measured as a proxy for total cholesterol  
138 given that the ratio of free to total cholesterol is relatively constant (39). Hereafter, free  
139 cholesterol-adjusted TOHs refer to the TOH levels after adjustment of free un-esterified  
140 cholesterol (i.e., TOH/cholesterol). Both raw TOH and free-cholesterol-adjusted TOH were used  
141 in this study because as a lipid-soluble vitamin, plasma vitE concentration varies by blood lipid  
142 levels (40).

### 143 Genotyping

144 Genome-wide genotypes were assayed on a subset of unrelated RAS men in the vitE arm  
145 ( $n = 625$ ). The vitE arm was selected for genotyping, rather than the vitE+Se arm, due to  
146 potential synergistic effects of Se supplementation. Participant samples of blood buffy coat,  
147 collected between 2004 and 2008 at the year 3 annual visit, were stored in a freezer at -80°C in  
148 the Human Metabolic Research Unit, Cornell University. In 2011, samples were shipped to the  
149 Center for Inherited Disease Research Laboratory, and DNA was extracted from peripheral

150 blood leukocytes via the Puregene Blood Kit chemistry on an Autopure LS automated DNA  
151 purification instrument (Qiagen, Valencia, CA). In 2016, the Biotechnology Resource Center at  
152 Cornell University quantified the DNA concentrations using the Quantifluor dsDNA kit via the  
153 Spectra Max M2 plate reader (Molecular Devices, San Jose, CA), and samples were re-  
154 suspended in the hydration buffer (10mM Tris-Cl, 1mM EDTA, pH 8.0) to normalize  
155 concentrations, and then sent to the Northwest Genomics Center at University of Washington on  
156 dry ice in April 2016 for genotyping.

157         The Illumina Infinium<sup>®</sup> Expanded Multi-Ethnic Genotyping Array (MEGA<sup>ex</sup>) (Illumina  
158 Inc., San Diego, CA, USA) was used to genotype more than 2 million genetic markers in 618  
159 participants (7 participants were excluded due to very low DNA concentration). After excluding  
160 participants with failed call rate ( $n = 15$ ), genotype data were available for 440 participants of  
161 European ancestry [EAs] and 141 participants of African ancestry [AAs]. Quality control (QC)  
162 was applied on the genotyped individuals and the single nucleotide polymorphisms (SNPs). At  
163 the individual level, the QC filters included: (1) missing call rate > 3%, (2) duplicate sample  
164 (identity-by-state > 0.9), (3) first degree relative (identity-by-descent > 0.4), and (4) excessive  
165 homozygosity; there were 9 EAs and 1 AA excluded, leaving 431 EAs and 140 AAs. For the  
166 genetic analysis of plasma change in TOHs, the final sample size with all covariate information  
167 available was 555 ( $N_{EA} = 417$ , and  $N_{AA} = 138$ ). At the SNP level, the QC filters included: (1)  
168 missing rate > 3%, (2) Hardy-Weinberg equilibrium p-value <  $1 \times 10^{-4}$  and (3) duplicate SNPs;  
169 these QC steps reduced the total genotyped SNP count from 2,036,060 to 1,671,215 for EAs and  
170 1,662,290 for AAs. Genotype imputation was then performed based on the Haplotype Reference  
171 Consortium panel (version r1.1 2016) (41) using the Michigan Imputation Server. Given the  
172 sample size, we focused on variants with minor allele frequency (MAF) > 0.03 in both the



173 ancestry-relevant 1000 Genomes Phase 3 super population (EUR for EAs and AFR for AAs) and  
 174 the study population, resulting in a final set of 6,069,665 variants for EAs and 8,944,804 variants  
 175 for AAs.

176 Statistical Analysis of Plasma Vitamin E—Pulmonary Function Association

177 A dose-response analysis was used to test the association of change in plasma vitE  
 178 biomarker levels ( $\alpha$ -TOH and  $\gamma$ -TOH) in response to vitE supplementation (“ $\Delta$ vitE” refers to  
 179 change in  $\alpha$ -TOH, the primary exposure of interest) with annual rate of change in FEV<sub>1</sub> in the  
 180 two vitE arms. A mixed-effects linear regression model was used to account for the repeated  
 181 PFTs for each participant. The FEV<sub>1</sub> value of each participant at each time point was the  
 182 dependent variable in the model, with a variable for time as an independent variable that  
 183 reflected the effect of one year of aging on change in pulmonary function (i.e., annual rate of  
 184 change in FEV<sub>1</sub>). The association of  $\Delta$ vitE with annual rate of change in FEV<sub>1</sub> was modeled as  
 185 an interaction term between  $\Delta$ vitE and the time variable in the linear mixed-effects model (see  
 186 equation below). The association was adjusted for covariates, including PFT-related factors such  
 187 as age, height, ancestry, smoking status, cigarettes per day (current smokers only), as well as vitE  
 188 status-related factors such as treatment arm (vitE arm, vitE+Se arm), baseline  $\alpha$ -TOH,  $\gamma$ -TOH,  
 189 and free cholesterol concentrations.

$$\begin{aligned}
 190 \quad & \text{FEV}_{1ij} = \beta_0(\text{intercept}) + \beta_1(\text{time}_{ij}) + \beta_2(\Delta \text{ vitE}) \\
 191 \quad & + \beta_3(\Delta \text{ vitE} \times \text{time}_{ij}) + \mu_i(\text{random effect of subject/individual}) \\
 192 \quad & + \varepsilon_{ij}(\text{random error}) + (\text{other covariates})
 \end{aligned}$$

193 where  $i = i^{\text{th}}$  individual,  $j = j^{\text{th}}$  PFT measure

194 Sensitivity analyses explored subgroups where we hypothesized a stronger  $\Delta$ vitE-FEV<sub>1</sub>  
 195 association. The first sensitivity analysis limited participants to those who were adherent to the

196 intervention, defined as using  $\geq 80\%$  of the vitE supplement pills. Next, the analysis was further  
197 limited to adherent men who were responders to the vitE supplementation. Given that there was a  
198 decrease in plasma vitE concentration over 3 years, on average, in a subset of randomly selected  
199 participants in the placebo arm ( $n = 91$ ; mean  $\Delta\text{vitE} -3.8 \mu\text{mol/L}$ ), responders to the vitE  
200 supplementation in the two intervention arms were defined as participants with a plasma  $\Delta\text{vitE}$   
201 value greater than the mean  $\Delta\text{vitE}$  in the placebo arm. We chose the mean  $\Delta\text{vitE}$  in the placebo  
202 arm as the reference point, instead of 0 (i.e., no change), because the change in plasma vitE over  
203 3 years without a supplement is best estimated by the  $\Delta\text{vitE}$  value in the placebo group (**Figure**  
204 **2**). Results were robust to this choice.

205 The significance threshold for all analyses was set at two-sided  $P \leq 0.05$ . Non-linearity  
206 was examined by including a square term for  $\Delta\text{vitE}$ . The influence of one outlier for  $\Delta\text{vitE}$  was  
207 examined by comparing the results with and without the outlier. Possible effect modification of  
208 the  $\Delta\text{vitE}$ -FEV<sub>1</sub> association by smoking status, by treatment arm, and by ancestry was examined  
209 in separate models via a 3-way interaction term (each putative effect modifier  $\times \Delta\text{vitE} \times \text{time}$ ).

#### 210 Statistical Analysis of Non-Genetic Factors on $\Delta\text{vitE}$

211 We completed a systematic search of the literature for reports of non-genetic factors  
212 associated with plasma vitE concentration. For each factor identified, a further literature review  
213 sought to identify the biological plausibility of the putative association (**Supplemental**  
214 **methods**), leading to a final set of factors that were tested individually and then simultaneously  
215 in joint models. The variables tested were ancestry, intervention arm, and smoking status  
216 measured over the course of the study, and baseline values for age, BMI,  $\alpha$ -TOH concentration,  
217  $\gamma$ -TOH concentration, free cholesterol concentration, plasma Se concentration, and dietary  
218 intakes of vitamin C, fiber, alcohol. The dietary information was collected by a 120-item food

219 frequency questionnaire (FFQ) administered at study baseline (42) to assess average food intake  
220 during the preceding 12 months, developed by the Nutrition Assessment Shared Resource  
221 (NASR) of Fred Hutchinson Cancer Research Center (Seattle, WA). Nutrient calculations were  
222 performed using the Nutrient Data System for Research (NDSR) software (version 2010),  
223 developed by the Nutrition Coordinating Center, University of Minnesota (Minneapolis, MN).  
224 For smoking status over the course of the study, we categorized the participants into never,  
225 former (stopped smoking prior to enrollment), intermittent (on and off smoking during the  
226 study), and persistent smokers to account for changes over the course of the study. We grouped  
227 intermittent and persistent smokers (i.e., current smokers during the study) to increase the power  
228 to detect associations. Linear regression models in SAS (version 9.4, SAS Institute, Cary, NC)  
229 tested the association of non-genetic factors with both raw  $\Delta\text{vitE}$  and free-cholesterol-adjusted  
230  $\Delta\text{vitE}$ . The total  $R^2$  denoted the percent of variability in  $\Delta\text{vitE}$  explained by the full model, and  
231 the individual  $R^2$  denoted the estimated variability explained by each individual factor (e.g.,  
232 ancestry, baseline TOH concentration), which was calculated as the difference between total  $R^2$   
233 with and without the factor in the model.

#### 234 Statistical Analysis of Genetic Variants on $\Delta\text{vitE}$

235 We conducted agnostic (i.e., GWAS) analyses in order to identify SNPs associated with  
236  $\Delta\text{vitE}$ . We tested SNPs for associations under an additive model using imputed genotype dosage  
237 values (a fractional value between 0 and 2 indicating the expected number of minor allele copies)  
238 to account for any imputation uncertainty (43). GWAS analyses stratified by ancestry ( $N_{EA} =$   
239 417,  $N_{AA} = 138$ ) were performed in rvtests (44) and then meta-analyzed using METAL (45) for  
240 each of four vitE phenotypes (raw  $\Delta\text{vitE}$ , free-cholesterol-adjusted  $\Delta\text{vitE}$ , raw  $\Delta\gamma\text{-TOH}$ , and free-  
241 cholesterol-adjusted  $\Delta\gamma\text{-TOH}$ ) in models adjusted for age, baseline TOH concentration, and

242 principal components to account for population substructure. We used the GWAS results to  
243 conduct *in-silico* look-up associations for two SNPs that were discovered in a previous GWAS of  
244 post-vitE-supplementation plasma  $\alpha$ -TOH in heavy smokers ( $P < 5 \times 10^{-7}$ , accounting for 549,989  
245 tested SNPs in the previous study) (35); we applied a Bonferroni-corrected p-value threshold of  
246 0.025 ( $\alpha=0.05/2$  SNPs). Any SNPs that we replicated were further examined in models that  
247 included additional adjustment for the set of previously reported non-genetic covariates  
248 (**Supplemental Methods**) using SAS (version 9.4), which were not included in our parsimonious  
249 GWAS model that was designed to optimize statistical power.

250

## 251 **Results**

### 252 Participant Characteristics

253 1,144 participants were included in the model of annual rate of change in FEV<sub>1</sub>: N<sub>EA</sub> =  
254 874 (76.4%) and N<sub>AA</sub> = 270 (23.6%). The mean age of included participants was 63 years, and  
255 most participants had a history of smoking (49% former smokers, 19% current smokers) (**Table**  
256 **1**) and were overweight (48%) or obese (34%).

257 On average, participants in the vitE arms showed an *increase* in plasma  $\alpha$ -TOH after 3  
258 years of vitE supplementation; the mean (SD) increase in plasma  $\alpha$ -TOH was 8.2 (12.5)  $\mu$ mol/L  
259 in the vitE arm and 7.4 (14.5)  $\mu$ mol/L in the vitE+Se arm (**Supplemental Table 1**). In contrast,  
260 plasma  $\alpha$ -TOH among participants in the double placebo arm (no vitE supplementation)  
261 decreased on average [mean  $\Delta$ : -3.8  $\mu$ mol/L  $\alpha$ -TOH (SD = 8.5),  $P = 4.9 \times 10^{-5}$ , **Figure 2**].  
262 Participants in the double placebo arm who reported use of pre-study vitE supplementation (>50  
263 IU/d  $\alpha$ -TOH or with other multivitamins) (17%) had a greater decrease in their plasma vitE level  
264 over 3 years (mean  $\Delta$ vitE = -19  $\mu$ mol/L vs. -2.4  $\mu$ mol/L for participants not reporting pre-study

265 vitE supplementation). For participants in the vitE arms, the increase in plasma vitE level was  
266 lower in participants who took pre-study vitE supplements (21%) (mean  $\Delta$ vitE = +2.7  $\mu$ mol/L vs.  
267 +9.2  $\mu$ mol/L for those who did not take pre-study vitE supplementation).

268 Consistent with the change in plasma  $\alpha$ -TOH, there was a notable change in plasma  $\gamma$ -  
269 TOH in participants in the vitE arms; plasma  $\gamma$ -TOH decreased by an average of 1.7  $\mu$ mol/L in  
270 both vitE arms (SD = 2.4 and 2.6, respectively, in vitE arm and vitE+Se), but there was little to  
271 no change in the double placebo arm [mean  $\Delta$ : +0.5  $\mu$ mol/L (SD = 2.9),  $P = 0.10$ ]  
272 (**Supplemental Table 1**). Six percent of participants were at risk of vitE deficiency at baseline  
273 using the clinical threshold of 12  $\mu$ mol/L (46), and this dropped to 2% in the vitE arms after 3  
274 years of supplementation. The two vitE intervention arms were similar in baseline characteristics  
275 and change in plasma tocopherol concentrations (**Table 1 and Supplemental Table 1**).  
276 Although there was a statistically significant difference in BMI ( $P = 0.0019$ ), the difference was  
277 not considered biologically meaningful with mean BMI of 29.3 in the vitE arm and 28.4 in the  
278 vitE+Se arm. While there was little to no correlation between baseline concentrations of  $\alpha$ -TOH  
279 and  $\gamma$ -TOH in participants in the two vitE arms (Pearson  $r = 0.018$ ,  $P=0.53$ ), there was an inverse  
280 correlation between  $\Delta$ vitE and  $\Delta\gamma$ -TOH (Pearson  $r = -0.22$ ,  $P<0.0001$ ).

281 The mean increase in  $\Delta$ vitE after 3-years of supplementation was significantly higher in  
282 EAs compared with AAs in the vitE arm ( $P_{EA \text{ vs } AA} = 0.010$ , 9.0  $\mu$ mol/L versus 5.9  $\mu$ mol/L,  
283 respectively), with similar direction, but lower magnitude differences in the vitE+Se arm ( $P_{EA \text{ vs } AA} = 0.60$ , 7.5  $\mu$ mol/L versus 6.9  $\mu$ mol/L). The greater increase in plasma vitE levels in EAs was  
284 not related to differences by ancestry group in pre-study vitE supplement use (i.e., a greater  
285 increase due to less pre-study vitE use). Indeed, the proportion of EAs reporting pre-study vitE  
286 supplement use was greater (23%) compared to AAs (13%).  
287

288

289 Plasma  $\Delta$ vitE and Longitudinal Pulmonary Function Decline

290 Plasma  $\Delta$ vitE was associated with longitudinal FEV<sub>1</sub> decline in adherent participants who  
291 responded to the vitE supplement ( $\Delta$ vitE  $\geq$ -3.8  $\mu$ mol/L) (**Table 2**), and there was little to no  
292 association of  $\Delta\gamma$ -TOH (**Supplemental Table 2**). In the full sample, an increase of 1  $\mu$ mol/mmol  
293 in free-cholesterol-adjusted  $\Delta$ vitE was associated with a 0.96 mL/year (SD=0.60) attenuation in  
294 annual FEV<sub>1</sub> decline ( $P = 0.11$ ). The effect size increased in sensitivity analyses as follows: men  
295 adherent to the intervention [increase of 1  $\mu$ mol/mmol in free-cholesterol-adjusted  $\Delta$ vitE  
296 associated with a +1.36 mL/year (SE = 0.78) attenuation in annual FEV<sub>1</sub> decline,  $P = 0.082$ ];  
297 adherent participants who responded to the vitE supplementation [+2.22 mL/year (SD = 0.90),  $P$   
298 = 0.014]. Overall, there was evidence that an increase in free-cholesterol-adjusted  $\Delta$ vitE was  
299 associated with attenuation in FEV<sub>1</sub> decline, with no evidence of non-linearity ( $P = 0.69$ ). In  
300 adherent participants who responded to the intervention, a 1 SD greater  $\Delta$ vitE ( $\sim$ 4  $\mu$ mol/mmol  
301 free cholesterol) was associated with an attenuation of  $\sim$ 9 mL/year in FEV<sub>1</sub> decline. Consistent  
302 trends were observed for  $\Delta$ vitE without adjusting free cholesterol (**Table 2**).

303 Smoking status modified the association of plasma  $\Delta$ vitE with FEV<sub>1</sub> decline ( $P_{\text{smoking}}$   
304 interaction  $< 0.05$ , **Table 2**). An increase in free-cholesterol-adjusted  $\Delta$ vitE was significantly  
305 associated with attenuation in FEV<sub>1</sub> decline in never smokers ( $P = 0.017$ ) with a similar but not  
306 statistically significant trend in current smokers ( $P = 0.079$ ), and, contrary to expectation, little to  
307 no association in former smokers ( $P = 0.45$ , **Table 2**). To put the effect magnitude in context, 1  
308 SD higher free-cholesterol-adjusted  $\Delta$ vitE ( $\sim$ 4  $\mu$ mol/mmol free cholesterol) was associated with  
309 9.7 mL/yr and 11.0 mL/yr attenuation in FEV<sub>1</sub> decline in never and current smokers,  
310 respectively. The same trend was observed for raw  $\Delta$ vitE (**Table 2**), and in sensitivity analysis

311 limited to adherent men (**Supplemental Table 3**). Neither ancestry (AA, EA) nor treatment arm  
312 (vitE, vitE+Se) modified the association of  $\Delta$ vitE with FEV<sub>1</sub> decline ( $P_{\text{interaction}} = 0.85$  and  $0.43$   
313 for ancestry and treatment arm, respectively).

#### 314 Non-Genetic Factors and Plasma $\Delta$ vitE

315 Plasma  $\Delta$ vitE values ranged from  $-55 \mu\text{mol/L}$  to  $+109 \mu\text{mol/L}$  in the two vitE arms  
316 [**Figure 2**, mean (SD) of  $7.8 (13.5)$ , with no difference between arms,  $P = 0.68$ ]. Higher  $\alpha$ -TOH  
317 at the study baseline was associated with a *lower* increase in  $\Delta$ vitE ( $P < 0.0001$ ), while *higher*  
318 free cholesterol and *higher*  $\gamma$ -TOH at baseline were associated with a *greater* increase in  $\Delta$ vitE  
319 ( $P < 0.0001$ ) (**Table 3**). Ancestry was associated with  $\Delta$ vitE ( $P < 0.0001$ ), with a smaller  
320 increase in  $\Delta$ vitE in African American men and generally this pattern persisted regardless of  
321 smoking status (**Supplemental Table 4**). There was little to no association between age, BMI,  
322 smoking status, and other nutrition factors, including baseline plasma Se concentration, dietary  
323 intake of vitamin C, fiber, and alcohol in relation to  $\Delta$ vitE ( $P > 0.05$ ). Overall, we saw consistent  
324 findings between raw and free-cholesterol-adjusted  $\Delta\alpha$ -TOH (**Table 3**). The fully adjusted model  
325 explained 18.7% of the variability ( $R^2$ ) in  $\Delta$ vitE in the two vitamin E arms ( $n = 1,144$ ), and  
326 baseline concentrations of  $\alpha$ -TOH,  $\gamma$ -TOH, free cholesterol and ancestry explained 10.9%, 1.7%,  
327 1.2%, and 1.6% of the variability, respectively.

#### 328 Genetic Factors and Plasma $\Delta$ vitE

329 GWAS analyses revealed no genome-wide significant loci ( $P < 5 \times 10^{-8}$ ) for change in  
330 TOH concentration (either  $\alpha$ - or  $\gamma$ -TOH) in the vitE arm (results not shown). We used the GWAS  
331 results to study 2 SNPs (rs964184 and rs2108622) that were previously reported in a GWAS of  
332 circulating  $\alpha$ -TOH measured after 3-years of vitE supplementation in male current smokers, but  
333 were not tested for replication (35). We replicated one SNP: rs2108622 was associated with

334  $\Delta$ vitE after 3 years of vitE supplementation in the healthy male participants in the RAS, with *P*-  
335 value passing the Bonferroni-corrected threshold for replication ( $P < 0.025$ ). Rs2108622, a  
336 missense SNP in the cytochrome P450 family 4 subfamily F member 2 (*CYP4F2*) gene on  
337 chromosome 19, was directly genotyped on the MEGA<sup>ex</sup> array, so its dosages were 0 (major  
338 allele homozygote), 1 (heterozygote), and 2 (minor allele homozygote). When the genotype was  
339 modeled as a categorical variable, heterozygotes for the rs2108622 minor allele (*CT* genotype)  
340 had a +1.75  $\mu\text{mol/L}$   $\Delta$ vitE, compared to homozygotes for the major allele (*CC* genotype),  
341 whereas homozygotes for the minor allele (*TT* genotype) had a +5.66  $\mu\text{mol/L}$   $\Delta$ vitE, compared to  
342 *CC* genotype.

343         The mean  $\Delta$ vitE for participants with 0, 1, 2 minor alleles of rs2108622 was 7.6  $\mu\text{mol/L}$ ,  
344 9.5  $\mu\text{mol/L}$ , 12.7  $\mu\text{mol/L}$  in EAs, and ancestry-specific analyses revealed a consistent direction  
345 of association for rs2108622 ( $P = 0.61$  for interaction with ancestry; mean  $\Delta$ vitE for 0, 1, 2 minor  
346 alleles was 5.8  $\mu\text{mol/L}$ , 6.0  $\mu\text{mol/L}$ , 12.9  $\mu\text{mol/L}$  in AAs). Thus, findings with the two ancestries  
347 combined are presented herein. In the fully adjusted model where the number of SNP alleles was  
348 modelled as a continuous variable, each additional copy of the rs2108622-*T* minor allele  
349 (frequency = 31% in EAs and 13% in AAs) was associated with 2.36  $\mu\text{mol/L}$  *greater* increase in  
350  $\Delta$ vitE ( $P = 0.0032$ , **Table 4**), compared to the *C* major allele. This effect magnitude is ~20% of 1  
351 SD of  $\Delta$ vitE in the vitE arm (SD = 12.5  $\mu\text{mol/L}$ ). In addition, this SNP explained about a third of  
352 the variability ( $R^2$ ) in  $\Delta$ vitE that was initially explained by ancestry (without rs2108622 in the  
353 model, ancestry explained ~2.5% of  $\Delta$ vitE variability; with rs2108622 in the model, ancestry  
354 explained ~1.7% of  $\Delta$ vitE variability). A consistent direction of association was observed in  
355 models of free-cholesterol-adjusted  $\Delta\alpha$ -TOH, but findings were not statistically significant ( $P =$   
356 0.33). There was no evidence for rs2108622  $\times$  smoking interaction ( $P = 0.65$ ). The fully adjusted



357 model explained 18.3% of the variability in plasma  $\Delta\alpha$ -TOH in the vitE arm ( $n = 555$ ): baseline  
358 concentrations of  $\alpha$ -TOH,  $\gamma$ -TOH, free cholesterol, ancestry, and rs2108622-T explained 9.2%,  
359 1.7%, 1.3%, 1.7%, and 1.3% of the variability, respectively.

360

### 361 *Discussion*

362 We hypothesized that the effect of vitE supplementation on pulmonary function decline  
363 would vary across participants in an RCT because of inter-individual variability in the response  
364 to vitE supplementation. To address this question, we estimated the longitudinal association of  
365 change in vitE status with change in pulmonary function using a dose-response analysis that  
366 leveraged a biomarker (change in plasma-measured vitE level) to quantify the treatment  
367 exposure. We hypothesized that the associations would be stronger using this more direct  
368 measure of treatment exposure compared to the intention-to-treat analysis based on the treatment  
369 assignment. Our findings supported the hypothesis, showing that an increase in  $\Delta$ vitE was  
370 associated with an attenuated decline in FEV<sub>1</sub> in this RCT of generally healthy males  $\geq 50$  years  
371 of age, particularly in sensitivity analyses focused on adherent vitE supplement responders, such  
372 that a 1 SD greater increase in plasma free-cholesterol-adjusted  $\Delta$ vitE had an effect on FEV<sub>1</sub>  
373 decline that was about one-quarter of the effect of a year of aging, but in the opposite direction.  
374 Smoking modified the association such that the beneficial effect of vitE supplementation was  
375 statistically significant in never smokers, with less significant effects in current smokers, and  
376 little to no effect in former smokers.

377 To the best of our knowledge, the only prior longitudinal study, which investigated the  
378 association of serum  $\alpha$ -TOH at study baseline with 8-year decline in pulmonary function,  
379 reported that heavy smokers with low baseline serum  $\alpha$ -TOH concentration predicted the

380 steepest FEV<sub>1</sub> decline (24). The previous intention-to-treat analysis in the RAS (25) estimated  
381 the treatment effect by study arm and reported a beneficial, but not statistically significant ( $P =$   
382 0.19), effect of vitE supplementation on longitudinal pulmonary function; the mean rate of  
383 decline in FEV<sub>1</sub> in the vitE arm was -33 mL/year compared to -39 mL/year in the placebo arm.  
384 The early termination of SELECT led to a loss of power in the RAS to detect the intervention  
385 effects. The dose-response findings reported herein using the  $\Delta$ vitE biomarker support a  
386 beneficial effect of vitE supplementation on preservation of pulmonary function. These findings  
387 warrant further study to consolidate the causal inference and indicate that exploring inter-  
388 individual response to nutrition interventions is informative.

389         Prior studies reported that current smokers experienced a faster disappearance of  $\alpha$ -TOH  
390 in the circulation and used more  $\alpha$ -TOH to combat oxidative stress compared to nonsmokers (47,  
391 48). However, even though we found a significantly lower vitE concentration at baseline in  
392 current smokers compared to never and former smokers (19.6  $\mu$ mol/L, 22.4  $\mu$ mol/L, and 22.5  
393  $\mu$ mol/L, respectively,  $P < 0.0005$ ), there was no difference in  $\Delta$ vitE by smoking status after 3-  
394 year vitE supplementation (7.8  $\mu$ mol/L, 8.0  $\mu$ mol/L, and 7.7  $\mu$ mol/L, respectively,  $P > 0.75$ ). Our  
395 test of effect modification by smoking status led to the unexpected finding that an increase in  
396 vitE attenuated pulmonary function decline in never smokers and current smokers, but not in  
397 former smokers. Future studies are needed to replicate the smoking-modified effect observed in  
398 this study and, if confirmed, to investigate tissue-specific  $\alpha$ -TOH concentrations after vitE  
399 supplementation across all smoking groups so as to better understand the mechanism.

400         We further hypothesized that genetic variation may contribute to the inter-individual  
401 variability in  $\Delta$ vitE. We found that the minor allele ( $T$ ) of rs2108622 on *CYP4F2* was associated  
402 with greater  $\Delta$ vitE ( $P = 0.0032$ ), and this finding partly explained the association of ancestry

403 with  $\Delta$ vitE. In the fully adjusted model, rs2108622 explained variability in  $\Delta\alpha$ -TOH equivalent  
404 to that explained by plasma free cholesterol, which is a key predictor of plasma  $\alpha$ -TOH  
405 concentration. This *CYP4F2* SNP (rs2108622) passed genome-wide significance in a previous  
406 GWAS of  $\Delta$ vitE conducted in a male heavy smoker population, but the finding was not  
407 replicated prior to the study reported herein. Given our population of healthy males, the  
408 replication provides important evidence in support of the generalizability of this finding.

409         The enzyme encoded by the *CYP4F2* gene has been shown to be the only one among the  
410 cytochrome P450 enzymes that has  $\omega$ -hydroxylase activity for vitE catabolism (e.g.,  $\alpha$ - and  $\gamma$ -  
411 TOH) in the liver (49, 50). The rs2108622-*T* allele results in a methionine, instead of a valine, at  
412 position 433 of the *CYP4F2* enzyme, and a prior study showed that the *CYP4F2* enzyme goes  
413 through faster degradation by the proteasome (51) when methionine is present. If true, persons  
414 with the *T* allele would have more  $\alpha$ -TOH in the liver available for  $\alpha$ -TTP transport into the  
415 circulation, leading to higher plasma  $\alpha$ -TOH. Consistent with this proposed mechanism, we  
416 observed that the EA population, with a higher frequency of rs2108622-*T* minor allele (31%  
417 *versus* 13% in AA, similar to those in the 1000 Genomes Project European [29%] and African  
418 [8%] populations), had a greater  $\Delta\alpha$ -TOH after supplementation. A candidate gene study of 2  
419 SNPs on the *CYP4F2* gene also reported an association of rs2108622-*T* with a greater increase in  
420 plasma vitE in patients with nonalcoholic fatty liver disease (52).

421         Several limitations deserve mention. First, at the time of this study, genotype data were  
422 available only for participants in the vitE arm ( $n = 555$ ), which limited power to detect  
423 significant associations at the genome-wide threshold ( $P < 5 \times 10^{-8}$ ). Nevertheless, we replicated  
424 one missense SNP (rs2108622) reported in a previous GWAS, surpassing the Bonferroni-  
425 corrected p-value threshold for testing two candidate SNPs ( $P < 0.025$ ) (35). Secondly, while our

426 study did not measure all non-genetic factors identified in the prior literature related to plasma  
427 vitE, such as waist circumference (WC) and waist-to-hip ratio (WHR) (53), the factors we  
428 investigated were representative of the unmeasured ones (e.g.,  $r > 0.60$  for the correlations of  
429 BMI with WC and WHR (54, 55)). Third, the randomized treatment group variable was retained  
430 in models because plasma  $\Delta$ vitE was used to quantify the biological dose of the treatment  
431 exposure in the vitE intervention arms rather than the initial intent-to-treat assignment. We found  
432 that the association of  $\Delta$ vitE with pulmonary function was largely unchanged with and without  
433 adjusting for potential confounding factors (e.g., age, smoking status, baseline nutriture),  
434 although we cannot fully rule out residual confounding. Finally, because the RAS participants  
435 were overall healthy males over 50 years old, the generalizability of the study may be limited,  
436 and whether the same findings would apply to females, to COPD patients, or to other ancestries  
437 beyond EAs and AAs needs further investigation.

438         In addition, there are several important considerations. First, regarding the timing of the  
439 study intervention and the measurement of PFTs, since the RAS was a post-randomization  
440 ancillary study to SELECT, no PFT data were available for the pre-intervention time period.  
441 Study supplementation was discontinued in October 2008 due to no benefit of the intervention on  
442 prostate cancer (36). Although PFTs were measured beyond the end of supplementation, only  
443 PFTs measured prior to March 1, 2009 were included in order to provide a conservative estimate  
444 of the effect of vitE intervention (4 months beyond the termination of supplements). Moreover,  
445 due to the discontinuation of SELECT, 65% of RAS participants completed  $\geq 2$  PFTs, leading to  
446 a loss of power in the intention-to-treat analysis by not having longitudinal PFT measures  
447 available on the full cohort (25). Given that the termination of study supplementation was an  
448 independent event unrelated to the timing of annual study visits for the participants, we assumed

449 that the RAS men with  $\geq 2$  PFTs comprised a random sample of the entire RAS population. In  
450 support of this assumption, the distribution of baseline characteristics including age, height, body  
451 mass index (BMI), ancestry, and smoking status were similar comparing men with and without  
452  $\geq 2$  PFTs (data not shown). Finally, the findings were consistent in analyses of  $\Delta$ vitE or  
453 cholesterol-adjusted  $\Delta$ vitE although not all findings were statistically significant.

454 This study examines both non-genetic and genetic factors related to  $\Delta$ vitE after vitE  
455 supplementation in a generally healthy population, with valid and reproducible measurements of  
456 longitudinal plasma vitE status (baseline and year 3, **Supplemental methods**) and pulmonary  
457 function (1–5 times per individual). Previous studies investigating the determinants of plasma  $\alpha$ -  
458 TOH were mostly cross-sectional (53, 56-65) or based on interventions with small numbers of  
459 participants ( $n < 50$ ) (66, 67). The present study is unique in considering  $\Delta$ vitE in a relatively  
460 large sample size ( $n = 1,144$ ), which is important given inter-individual variability in  $\Delta$ vitE.

461 To summarize, a greater change in plasma  $\Delta$ vitE with vitE supplementation was  
462 associated with an attenuation in FEV<sub>1</sub> decline, which may indicate a feasible intervention to  
463 mitigate pulmonary function decline. In addition, we replicated one missense variant, rs2108622  
464 in the *CYP4F2* gene, from a previous GWAS of  $\Delta$ vitE in heavy smokers, which could partially  
465 explain variability in  $\Delta$ vitE after supplementation, as observed in our population of healthy males  
466 over 50 years old. This genetic finding contributes to the evidence base for precision nutrition by  
467 supporting that genetic subgroups respond differentially to dietary supplementation. Thus,  
468 participants with the rs2108622-T minor allele may need less vitE supplement, compared with  
469 individuals without this allele, to achieve the same amount of increase in plasma  $\Delta$ vitE.

### ***Acknowledgments***

We thank Alison Munson, John Le Barre, and Rachel Grant who were undergraduate research assistants contributing to the analytic work on the association of plasma vitE with pulmonary function and the vitE assay work. We also thank Professor Andrew Clark in the Department of Biological Statistics and Computational Biology at Cornell University for providing advice on the analysis and interpretation of the genetic findings. We would also like to thank Vicky A. Simon in the Human Nutritional Chemistry Service Laboratory at Cornell University for her assistance with the inventory and transferring of the DNA samples. We thank Jing Wu and the Biotechnology Resource Center (BRC) Genomics Facility at Cornell's Institute of Biotechnology for the quantification and re-adjustment of the DNA sample concentrations. We also want to thank the BRC Bioinformatics Facility for the storage and computational support of the genomic data. In addition, we want to thank Bonnie K. Patchen, PhD candidate in our research group, for providing insight into the interpretation of results. Last but not least, the authors also thank the SELECT/RAS staff, other investigators and the participants of the RAS study for their valuable contributions.

### ***Conflict of Interest***

The authors have no conflict of interest.

### ***Authorship's contribution***

JX, KAG, and PAC conceived and designed the study; NCG imputed the genome-wide data; JX, KAG, and NCG analyzed the data. JX, KAG, JMF, ARK, KBA, PJG, CMT, DBH, and PAC interpreted the results; AHA and RSP conducted the vitE assays; PAC, ARK, and CMT

designed RAS; PAC, KAG, AHA, and PJG collected data; JX, KAG, DBH, and PAC drafted the manuscript and had primary responsibility for final content; and all authors contributed to critical revision in preparation for publication.

### ***Data sharing***

Data described in the manuscript, code book, and analytic code will be made available upon request.

### ***Funding***

This research was supported by the National Heart, Lung, and Blood Institute (NHLBI) grants R01 HL071022 and R21 HL125574, and the National Cancer Institute/Division of Cancer Prevention grants U10 CA37429 and 5UM1CA182883. Genotyping services were provided through the RS&G Service by the Northwest Genomics Center at the University of Washington, Department of Genome Sciences, under U.S. Federal Government contract number HHSN268201100037C from the NHLBI. This research was also supported, in part, by the Cornell University Center for Vertebrate Genomics Scholarship Award (to J Xu), and the American Society for Nutrition Pfizer Predoctoral Fellowship (to J Xu). The study sponsors were not involved in study design, data collection, data analysis, data interpretation, report writing or decisions to submit the paper for publication. JX and PAC had final responsibility for the decision to submit for publication.

### ***Clinical Trial Registry Number***

The ClinicalTrials.gov identifier of the SELECT trial is NCT00006392 and the identifier of the RAS trial is NCT00063453.

## References

1. Mocchegiani E, Costarelli L, Giacconi R, Malavolta M, Basso A, Piacenza F, Ostan R, Cevenini E, Gonos ES, Franceschi C, et al. Vitamin E-gene interactions in aging and inflammatory age-related diseases: implications for treatment. A systematic review. *Ageing Res Rev.* 2014;14:81-101.
2. Brigham KL. Role of free radicals in lung injury. *Chest.* 1986;89(6):859-63.
3. Dow L, Tracey M, Villar A, Coggon D, Margetts BM, Campbell MJ, Holgate ST. Does dietary intake of vitamins C and E influence lung function in older people? *Am J Respir Crit Care Med.* 1996;154(5):1401-4.
4. Butland BK, Fehily AM, Elwood PC. Diet, lung function, and lung function decline in a cohort of 2512 middle aged men. *Thorax.* 2000;55(2):102-8.
5. Schunemann HJ, McCann S, Grant BJ, Trevisan M, Muti P, Freudenheim JL. Lung function in relation to intake of carotenoids and other antioxidant vitamins in a population-based study. *Am J Epidemiol.* 2002;155(5):463-71.
6. Hanson C, Lyden E, Furtado J, Campos H, Sparrow D, Vokonas P, Litonjua AA. Serum tocopherol levels and vitamin E intake are associated with lung function in the normative aging study. *Clin Nutr.* 2016;35(1):169-74.
7. Joshi P, Kim WJ, Lee SA. The effect of dietary antioxidant on the COPD risk: the community-based KoGES (Ansan-Anseong) cohort. *Int J Chron Obstruct Pulmon Dis.* 2015;10:2159-68.
8. Charles LE, Burchfiel CM, Mnatsakanova A, Fekedulegn D, Tinney-Zara C, Joseph PN, Schunemann HJ, Violanti JM, Andrew ME, Ochs-Balcom HM. Antioxidants and pulmonary function among police officers. *J Occup Environ Med.* 2010;52(11):1124-31.
9. Gilliland FD, Berhane KT, Li YF, Gauderman WJ, McConnell R, Peters J. Children's lung function and antioxidant vitamin, fruit, juice, and vegetable intake. *Am J Epidemiol.* 2003;158(6):576-84.
10. Tabak C, Smit HA, Rasanen L, Fidanza F, Menotti A, Nissinen A, Feskens EJ, Heederik D, Kromhout D. Dietary factors and pulmonary function: a cross sectional study in middle aged men from three European countries. *Thorax.* 1999;54(11):1021-6.
11. Hu G, Cassano PA. Antioxidant nutrients and pulmonary function: the Third National Health and Nutrition Examination Survey (NHANES III). *Am J Epidemiol.* 2000;151(10):975-81.
12. Marchese ME, Kumar R, Colangelo LA, Avila PC, Jacobs DR, Jr., Gross M, Sood A, Liu K, Cook-Mills JM. The vitamin E isoforms alpha-tocopherol and gamma-tocopherol have opposite associations with spirometric parameters: the CARDIA study. *Respir Res.* 2014;15:31.
13. Schunemann HJ, Grant BJ, Freudenheim JL, Muti P, Browne RW, Drake JA, Klocke RA, Trevisan M. The relation of serum levels of antioxidant vitamins C and E, retinol and carotenoids with pulmonary function in the general population. *Am J Respir Crit Care Med.* 2001;163(5):1246-55.
14. Grant BJ, Kudalkar DP, Muti P, McCann SE, Trevisan M, Freudenheim JL, Schunemann HJ. Relation between lung function and RBC distribution width in a population-based study. *Chest.* 2003;124(2):494-500.
15. McKeever TM, Lewis SA, Smit HA, Burney P, Cassano PA, Britton J. A multivariate analysis of serum nutrient levels and lung function. *Respir Res.* 2008;9:67.



16. Britton JR, Pavord ID, Richards KA, Knox AJ, Wisniewski AF, Lewis SA, Tattersfield AE, Weiss ST. Dietary antioxidant vitamin intake and lung function in the general population. *Am J Respir Crit Care Med*. 1995;151(5):1383-7.
17. Grievink L, Smit HA, Ocke MC, van 't Veer P, Kromhout D. Dietary intake of antioxidant (pro)-vitamins, respiratory symptoms and pulmonary function: the MORGEN study. *Thorax*. 1998;53(3):166-71.
18. Chen R, Tunstall-Pedoe H, Bolton-Smith C, Hannah MK, Morrison C. Association of dietary antioxidants and waist circumference with pulmonary function and airway obstruction. *Am J Epidemiol*. 2001;153(2):157-63.
19. Grievink L, de Waart FG, Schouten EG, Kok FJ. Serum carotenoids, alpha-tocopherol, and lung function among Dutch elderly. *Am J Respir Crit Care Med*. 2000;161(3 Pt 1):790-5.
20. Grievink L, Smit HA, Veer P, Brunekreef B, Kromhout D. Plasma concentrations of the antioxidants beta-carotene and alpha-tocopherol in relation to lung function. *Eur J Clin Nutr*. 1999;53(10):813-7.
21. Kelly Y, Sacker A, Marmot M. Nutrition and respiratory health in adults: findings from the health survey for Scotland. *The European respiratory journal*. 2003;21(4):664-71.
22. Molinie F, Favier A, Kauffmann F, Berr C. Effects of lipid peroxidation and antioxidant status on peak flow in a population aged 59-71 years: the EVA study. *Respir Med*. 2003;97(8):939-46.
23. Pearson P, Britton J, McKeever T, Lewis SA, Weiss S, Pavord I, Fogarty A. Lung function and blood levels of copper, selenium, vitamin C and vitamin E in the general population. *Eur J Clin Nutr*. 2005;59(9):1043-8.
24. Guenegou A, Leynaert B, Pin I, Le Moel G, Zureik M, Neukirch F. Serum carotenoids, vitamins A and E, and 8 year lung function decline in a general population. *Thorax*. 2006;61(4):320-6.
25. Cassano PA, Guertin KA, Kristal AR, Ritchie KE, Bertoia ML, Arnold KB, Crowley JJ, Hartline J, Goodman PJ, Tangen CM, et al. A randomized controlled trial of vitamin E and selenium on rate of decline in lung function. *Respir Res*. 2015;16:35.
26. Klein EA, Thompson IM, Jr., Tangen CM, Crowley JJ, Lucia MS, Goodman PJ, Minasian LM, Ford LG, Parnes HL, Gaziano JM, et al. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). *Jama*. 2011;306(14):1549-56.
27. Alpha-Tocopherol BCCPSG. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. *N Engl J Med*. 1994;330(15):1029-35.
28. Heart Outcomes Prevention Evaluation Study I, Yusuf S, Dagenais G, Pogue J, Bosch J, Sleight P. Vitamin E supplementation and cardiovascular events in high-risk patients. *N Engl J Med*. 2000;342(3):154-60.
29. Gupta SK. Intention-to-treat concept: A review. *Perspect Clin Res*. 2011;2(3):109-12.
30. Kussmann M, Fay LB. Nutrigenomics and personalized nutrition: science and concept. *Per Med*. 2008;5(5):447-55.
31. Doring F, Rimbach G, Lodge JK. In silico search for single nucleotide polymorphisms in genes important in vitamin E homeostasis. *IUBMB Life*. 2004;56(10):615-20.
32. Ferrucci L, Perry JR, Matteini A, Perola M, Tanaka T, Silander K, Rice N, Melzer D, Murray A, Cluett C, et al. Common variation in the beta-carotene 15,15'-monooxygenase 1 gene affects circulating levels of carotenoids: a genome-wide association study. *Am J Hum Genet*. 2009;84(2):123-33.

33. Major JM, Yu K, Wheeler W, Zhang H, Cornelis MC, Wright ME, Yeager M, Snyder K, Weinstein SJ, Mondul A, et al. Genome-wide association study identifies common variants associated with circulating vitamin E levels. *Hum Mol Genet.* 2011;20(19):3876-83.
34. Wood AR, Perry JR, Tanaka T, Hernandez DG, Zheng HF, Melzer D, Gibbs JR, Nalls MA, Weedon MN, Spector TD, et al. Imputation of variants from the 1000 Genomes Project modestly improves known associations and can identify low-frequency variant-phenotype associations undetected by HapMap based imputation. *PloS one.* 2013;8(5):e64343.
35. Major JM, Yu K, Chung CC, Weinstein SJ, Yeager M, Wheeler W, Snyder K, Wright ME, Virtamo J, Chanock S, et al. Genome-wide association study identifies three common variants associated with serologic response to vitamin E supplementation in men. *J Nutr.* 2012;142(5):866-71.
36. Lippman SM, Klein EA, Goodman PJ, Lucia MS, Thompson IM, Ford LG, Parnes HL, Minasian LM, Gaziano JM, Hartline JA, et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). *Jama.* 2009;301(1):39-51.
37. Barr RG, Stemple KJ, Mesia-Vela S, Basner RC, Derk SJ, Henneberger PK, Milton DK, Taveras B. Reproducibility and validity of a handheld spirometer. *Respir Care.* 2008;53(4):433-41.
38. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, Enright P, van der Grinten CP, Gustafsson P, et al. Standardisation of spirometry. *The European respiratory journal.* 2005;26(2):319-38.
39. Lopez A, Krehl WA, Hodges RE. Relationship between total cholesterol and cholesteryl esters with age in human blood plasma. *Am J Clin Nutr.* 1967;20(8):808-15.
40. Ford ES, Schleicher RL, Mokdad AH, Ajani UA, Liu S. Distribution of serum concentrations of alpha-tocopherol and gamma-tocopherol in the US population. *Am J Clin Nutr.* 2006;84(2):375-83.
41. Das S, Forer L, Schonherr S, Sidore C, Locke AE, Kwong A, Vrieze SI, Chew EY, Levy S, McGue M, et al. Next-generation genotype imputation service and methods. *Nature genetics.* 2016;48(10):1284-7.
42. Fred Hutch Food Frequency Questionnaires (FFQ) [Available from: <https://sharedresources.fredhutch.org/services/food-frequency-questionnaires-ffq>].
43. Marchini J, Howie B. Genotype imputation for genome-wide association studies. *Nat Rev Genet.* 2010;11(7):499-511.
44. Zhan X, Hu Y, Li B, Abecasis GR, Liu DJ. RVTESTS: an efficient and comprehensive tool for rare variant association analysis using sequence data. *Bioinformatics.* 2016;32(9):1423-6.
45. Willer CJ, Li Y, Abecasis GR. METAL: fast and efficient meta-analysis of genomewide association scans. *Bioinformatics.* 2010;26(17):2190-1.
46. Institute of Medicine (US). Panel on Dietary Antioxidants and Related Compounds. Dietary Reference Intakes for Vitamin C, Vitamin E, Selenium, and Carotenoids: A Report of the Panel on Dietary Antioxidants and Related Compounds. Washington, D.C.: National Academy Press; 2000.
47. Traber MG, Winklhofer-Roob BM, Roob JM, Khoschsorur G, Aigner R, Cross C, Ramakrishnan R, Brigelius-Flohe R. Vitamin E kinetics in smokers and nonsmokers. *Free Radic Biol Med.* 2001;31(11):1368-74.

48. Bruno RS, Ramakrishnan R, Montine TJ, Bray TM, Traber MG. {alpha}-Tocopherol disappearance is faster in cigarette smokers and is inversely related to their ascorbic acid status. *Am J Clin Nutr.* 2005;81(1):95-103.
49. Sontag TJ, Parker RS. Cytochrome P450 omega-hydroxylase pathway of tocopherol catabolism. Novel mechanism of regulation of vitamin E status. *J Biol Chem.* 2002;277(28):25290-6.
50. Parker RS, Sontag TJ, Swanson JE, McCormick CC. Discovery, characterization, and significance of the cytochrome P450 omega-hydroxylase pathway of vitamin E catabolism. *Ann N Y Acad Sci.* 2004;1031:13-21.
51. van Engen CE, Ofman R, Dijkstra IM, van Goethem TJ, Verheij E, Varin J, Vidaud M, Wanders RJ, Aubourg P, Kemp S, et al. CYP4F2 affects phenotypic outcome in adrenoleukodystrophy by modulating the clearance of very long-chain fatty acids. *Biochim Biophys Acta.* 2016;1862(10):1861-70.
52. Athinarayanan S, Wei R, Zhang M, Bai S, Traber MG, Yates K, Cummings OW, Molleston J, Liu W, Chalasani N. Genetic polymorphism of cytochrome P450 4F2, vitamin E level and histological response in adults and children with nonalcoholic fatty liver disease who participated in PIVENS and TONIC clinical trials. *PLoS one.* 2014;9(4):e95366.
53. Wallstrom P, Wirfalt E, Lahmann PH, Gullberg B, Janzon L, Berglund G. Serum concentrations of beta-carotene and alpha-tocopherol are associated with diet, smoking, and general and central adiposity. *Am J Clin Nutr.* 2001;73(4):777-85.
54. Vazquez G, Duval S, Jacobs DR, Jr., Silventoinen K. Comparison of body mass index, waist circumference, and waist/hip ratio in predicting incident diabetes: a meta-analysis. *Epidemiol Rev.* 2007;29:115-28.
55. Ohlson LO, Larsson B, Svardsudd K, Welin L, Eriksson H, Wilhelmsen L, Bjorntorp P, Tibblin G. The influence of body fat distribution on the incidence of diabetes mellitus. 13.5 years of follow-up of the participants in the study of men born in 1913. *Diabetes.* 1985;34(10):1055-8.
56. Abdulla KA, Um CY, Gross MD, Bostick RM. Circulating gamma-Tocopherol Concentrations Are Inversely Associated with Antioxidant Exposures and Directly Associated with Systemic Oxidative Stress and Inflammation in Adults. *J Nutr.* 2018;148(9):1453-61.
57. Waniek S, di Giuseppe R, Esatbeyoglu T, Plachta-Danielzik S, Ratjen I, Jacobs G, Nothlings U, Koch M, Schlesinger S, Rimbach G, et al. Vitamin E (alpha- and gamma-Tocopherol) Levels in the Community: Distribution, Clinical and Biochemical Correlates, and Association with Dietary Patterns. *Nutrients.* 2017;10(1).
58. Stuetz W, Weber D, Dolle ME, Jansen E, Grubeck-Loebenstien B, Fiegl S, Toussaint O, Bernhardt J, Gonos ES, Franceschi C, et al. Plasma Carotenoids, Tocopherols, and Retinol in the Age-Stratified (35-74 Years) General Population: A Cross-Sectional Study in Six European Countries. *Nutrients.* 2016;8(10).
59. Talegawkar SA, Johnson EJ, Carithers T, Taylor HA, Jr., Bogle ML, Tucker KL. Total alpha-tocopherol intakes are associated with serum alpha-tocopherol concentrations in African American adults. *J Nutr.* 2007;137(10):2297-303.
60. Galan P, Viteri FE, Bertrais S, Czernichow S, Faure H, Arnaud J, Ruffieux D, Chenal S, Arnault N, Favier A, et al. Serum concentrations of beta-carotene, vitamins C and E, zinc and selenium are influenced by sex, age, diet, smoking status, alcohol consumption and corpulence in a general French adult population. *Eur J Clin Nutr.* 2005;59(10):1181-90.

61. White E, Kristal AR, Shikany JM, Wilson AC, Chen C, Mares-Perlman JA, Masaki KH, Caan BJ. Correlates of serum alpha- and gamma-tocopherol in the Women's Health Initiative. *Ann Epidemiol.* 2001;11(2):136-44.
62. Vogel S, Contois JH, Tucker KL, Wilson PW, Schaefer EJ, Lammi-Keefe CJ. Plasma retinol and plasma and lipoprotein tocopherol and carotenoid concentrations in healthy elderly participants of the Framingham Heart Study. *Am J Clin Nutr.* 1997;66(4):950-8.
63. Ascherio A, Stampfer MJ, Colditz GA, Rimm EB, Litin L, Willett WC. Correlations of vitamin A and E intakes with the plasma concentrations of carotenoids and tocopherols among American men and women. *J Nutr.* 1992;122(9):1792-801.
64. Knekt P, Seppanen R, Aaran RK. Determinants of serum alpha-tocopherol in Finnish adults. *Prev Med.* 1988;17(6):725-35.
65. Willett WC, Stampfer MJ, Underwood BA, Speizer FE, Rosner B, Hennekens CH. Validation of a dietary questionnaire with plasma carotenoid and alpha-tocopherol levels. *Am J Clin Nutr.* 1983;38(4):631-9.
66. Switzer BR, Atwood JR, Stark AH, Hatch JW, Travis R, Ullrich F, Lyden ER, Wu X, Chiu Y, Smith JL. Plasma carotenoid and vitamins a and e concentrations in older African American women after wheat bran supplementation: effects of age, body mass and smoking history. *J Am Coll Nutr.* 2005;24(3):217-26.
67. Grolier P, Boirie Y, Levaux E, Brandolini M, Borel P, Azais-Braesco V, Beaufriere B, Ritz P. Age-related changes in plasma lycopene concentrations, but not in vitamin E, are associated with fat mass. *Br J Nutr.* 2000;84(5):711-6.

**Table 1. Characteristics of male participants with vitamin E supplementation in the Respiratory Ancillary Study ( $n = 1,144$ )<sup>1</sup>**

	<b>Overall (<math>n = 1144</math>)</b>	<b>Vitamin E + Selenium (<math>n = 565</math>)</b>	<b>Vitamin E + Placebo (<math>n = 579</math>)</b>	<b><math>P_{\text{vitE+Se vs vitE}}</math><sup>2</sup></b>
<b>Age (y)</b> <sup>3</sup>	62.6 (6.4)	62.7 (6.3)	62.5 (6.4)	0.57
<b>Ethnicity, N (%)</b> <sup>3</sup>				0.64
<b>European American</b>	874 (76)	435 (77)	439 (76)	
<b>African American</b>	270 (24)	130 (23)	140 (24)	
<b>Smoking Status, N (%)</b> <sup>4</sup>				0.98
<b>Never</b>	364 (32)	181 (32)	183 (32)	
<b>Former</b>	564 (49)	277 (49)	287 (50)	
<b>Current</b>	216 (19)	107 (19)	109 (19)	
<b>BMI (kg/m<sup>2</sup>)</b> <sup>3</sup>	28.9 (4.6)	28.4 (4.6)	29.3 (4.6)	<b>0.0019</b>
<b>Height (cm)</b> <sup>3</sup>	176.6 (7.1)	176.6 (7.0)	176.7 (7.1)	0.83
<b>FEV<sub>1</sub> (mL)</b> <sup>3</sup>	2986.8 (680.8)	2990.4 (669.1)	2983.2 (692.5)	0.86

<sup>1</sup> Data are presented as mean (standard deviation [SD]) in the table, and measured at baseline, unless otherwise noted.

<sup>2</sup> The p-value is to compare whether each characteristic in the vitE+Se arm significantly differed from that in the vitE arm. P-value is based on the t test for continuous variables or based on the chi-square test for categorical variables in the vitamin E arms (vitE+Se arm versus vitE arm). Significant  $P < 0.05$  is in bold.

<sup>3</sup> Measured at baseline.

<sup>4</sup> Smoking status refers to the status throughout the study such that former smoker is defined as someone who had quit smoking before getting enrolled in the study, whereas current smoker is defined as intermittent or persistent smokers over the course of the study.

Abbreviations: BMI, body mass index; FEV<sub>1</sub>, forced expiratory volume in the 1<sup>st</sup> second, vitE, vitamin E supplementation only arm; vitE+Se, vitamin E + selenium supplementation arm.

**Table 2. Association of plasma change in  $\alpha$ -tocopherol after 3-year vitamin E supplementation, and its interaction with smoking status, on annual rate of change in FEV<sub>1</sub><sup>1</sup>**

	$\Delta$ Raw $\alpha$ -TOH			$\Delta$ Adjusted $\alpha$ -TOH <sup>2</sup>		
	$\beta$ (SE) <sup>3</sup>	95% CI	P value <sup>4</sup>	$\beta$ (SE) <sup>3</sup>	95% CI	P value <sup>4</sup>
<b>Main effect model (<math>n = 1,142</math>)<sup>5</sup></b>						
<b>Full sample</b>	0.23 (0.20)	(-0.17, 0.63)	0.26	0.96 (0.60)	(-0.23, 2.14)	0.11
<b>Adherent sample<sup>6</sup> (<math>n = 775</math>)</b>	0.24 (0.25)	(-0.26, 0.73)	0.35	1.36 (0.78)	(-0.17, 2.89)	<i>0.082</i>
<b>Adherent sample who responded to the vitE supplement<sup>6,7</sup> (<math>n = 680</math>)</b>	0.67 (0.31)	(0.054, 1.28)	<b>0.033</b>	2.22 (0.90)	(0.45, 3.99)	<b>0.014</b>
<b>Smoking interaction model (<math>n = 1,142</math>)<sup>5</sup></b>						
			<b>P<sub>interaction</sub>=0.013<sup>8</sup></b>			<b>P<sub>interaction</sub>=0.032<sup>8</sup></b>
<b>Never smokers (<math>n = 364</math>)</b>	0.83 (0.35)	(0.15, 1.51)	<b>0.017</b>	2.43 (1.01)	(0.44, 4.42)	<b>0.017</b>
<b>Former smokers (<math>n = 564</math>)</b>	-0.41 (0.30)	(-0.99, 0.17)	0.17	-0.64 (0.86)	(-2.32, 1.04)	0.45
<b>Current smokers (<math>n = 214</math>)</b>	0.73 (0.48)	(-0.20, 1.67)	0.12	2.75 (1.57)	(-0.32, 5.82)	<i>0.079</i>

<sup>1</sup> All models were adjusted for age at baseline, height, ancestry, smoking status, smoking dose at baseline, treatment arm, baseline  $\alpha$ -tocopherol, baseline  $\gamma$ -tocopherol, and baseline free cholesterol (only in the model with raw  $\alpha$ -tocopherol values).

<sup>2</sup>  $\Delta$ Adjusted  $\alpha$ -TOH refers to the change in free-cholesterol-adjusted  $\alpha$ -tocopherol concentration from baseline to year 3.

<sup>3</sup>  $\beta$  was the coefficient of the  $\Delta\alpha$ -TOH  $\times$  time term in the main effect model. For the smoking interaction model, it was the coefficient of the  $\Delta\alpha$ -TOH  $\times$  time term for the reference group when each smoking status was set as the reference.

<sup>4</sup> P-value of the  $\Delta\alpha$ -TOH  $\times$  time term to test the association of  $\Delta\alpha$ -TOH on rate of change in FEV<sub>1</sub>. For the smoking interaction model, it was the p-value of  $\Delta\alpha$ -TOH  $\times$  time term for each smoking group (when it was set as the reference) in the model that included all smoking status. Significant  $P < 0.05$  is in bold and  $P < 0.10$  is italicized.

<sup>5</sup> 2 current smokers had missing data for smoking dose and thus were excluded in the statistical model.

<sup>6</sup> Adherent participants (defined as taking at least 80% of the supplement pills) during the 3 years of supplementation.

<sup>7</sup> Responder was defined as  $\Delta$ raw  $\alpha$ -TOH greater than the mean change in the placebo arm ( $-3.8 \mu\text{mol/L}$ ) after 3-year supplementation.

<sup>8</sup> The  $P_{\text{interaction}}$  value was for the 3-way interaction term ( $\Delta\alpha\text{-TOH} \times \text{time} \times \text{smoking status}$ ) to test whether the association of  $\Delta\alpha\text{-TOH}$  on rate of change in  $\text{FEV}_1$  differed by smoking status.

Abbreviations: CI, confidence interval.



**Table 3. Factors associated with plasma change in  $\alpha$ -tocopherol after 3-year vitamin E supplementation in the Respiratory****Ancillary Study ( $n = 1,135$ )<sup>1</sup>**

	$\Delta$ Raw $\alpha$ -TOH <sup>2</sup>		$\Delta$ Adjusted $\alpha$ -TOH <sup>3</sup>	
	$\beta$ (SE) <sup>4</sup>	P-value <sup>5</sup>	$\beta$ (SE) <sup>4</sup>	P-value <sup>5</sup>
<b>Baseline <math>\alpha</math>-tocopherol<sup>6</sup></b>	-0.64 (0.052)	< <b>0.0001</b>	-0.38 (0.039)	< <b>0.0001</b>
<b>Baseline <math>\gamma</math>-tocopherol<sup>6</sup></b>	0.82 (0.17)	< <b>0.0001</b>	1.31 (0.14)	< <b>0.0001</b>
<b>Cholesterol (<math>\mu</math>mol/L)</b>	0.0024 (0.00058)	< <b>0.0001</b>		
<b>Ancestry</b>				
<b>White</b>	4.43 (0.93)	< <b>0.0001</b>	1.71 (0.30)	< <b>0.0001</b>
<b>African American</b>	Ref	ref	ref	ref
<b>Treatment arm</b>				
<b>Vitamin E + Selenium</b>	-0.30 (0.73)	0.68	0.30 (0.24)	0.21
<b>Vitamin E + Placebo</b>	Ref	ref	ref	ref
<b>Age (year)</b>	-0.078 (0.059)	0.19	0.0082 (0.019)	0.67
<b>BMI (<math>\text{kg}/\text{m}^2</math>)</b>	0.044 (0.080)	0.58	0.013 (0.026)	0.63
<b>Smoking Status</b>		Type III = 0.53		Type III=0.40
<b>Current Smokers</b>	-1.16 (1.09)	0.29	-0.46 (0.35)	0.21
<b>Former Smokers</b>	-0.11 (0.83)	0.89	-0.039 (0.27)	0.88
<b>Never Smokers</b>	Ref	ref	ref	ref
<b>Baseline selenium concentration (parts per billion)</b>	-0.0024(0.0056)	0.67	-0.00064 (0.0018)	0.72
<b>Total vitamin C intake (mg)</b>	-0.00041 (0.0014)	0.78	0.00025 (0.00046)	0.60
<b>Dietary fiber intake (gram)</b>	0.043 (0.035)	0.22	0.0052 (0.011)	0.65
<b>Alcohol intake (gram)</b>	-0.0016 (0.018)	0.93	-0.0049 (0.0060)	0.41

<sup>1</sup> All factors shown in the table were modeled in the same multiple linear regression. Participants in the vitamin E + selenium arm and in the vitamin E + placebo arm were included. 9 participants had missing vitamin C, fiber, and alcohol intake and thus the sample size for this analysis was 1135.

<sup>2</sup> Total variability explained,  $R^2=18.7\%$ .

<sup>3</sup>  $\Delta$ Adjusted  $\alpha$ -TOH refers to the change in free-cholesterol-adjusted  $\alpha$ -tocopherol concentration from baseline to year 3. Total variability explained,  $R^2=19.5\%$ .

<sup>4</sup>  $\beta$  was the coefficient of the association of each factor with the change in  $\alpha$ -tocopherol phenotype.

<sup>5</sup> For each categorical variable, the type III p-value indicates whether the categorical variable was significant when being included in the model, while the p-value of each categorical level (except the reference group) indicates whether the coefficient significantly differed from that of the reference group. For each continuous variable, the p-value indicates whether the coefficient significantly differed from zero.

<sup>6</sup> The unit for baseline  $\alpha$ -tocopherol and  $\gamma$ -tocopherol concentrations is  $\mu\text{mol/L}$  when the outcome is the raw plasma change in  $\alpha$ -tocopherol concentration, and the unit is  $\mu\text{mol}/\text{mmol}$  free cholesterol when the outcome is the plasma change in free-cholesterol-adjusted  $\alpha$ -tocopherol concentration.

Abbreviations: BMI, body mass index.

**Table 4. The association of rs2108622-T with plasma change in  $\alpha$ -tocopherol for male participants randomized to the vitamin E only arm (400 IU/day all *rac*- $\alpha$ -tocopherol) in the Respiratory Ancillary Study ( $n = 555$ )**

	$\Delta$ Raw $\alpha$ -TOH		$\Delta$ Adjusted $\alpha$ -TOH <sup>1</sup>	
	$\beta$ (SE) <sup>2</sup>	P-value <sup>3</sup>	$\beta$ (SE) <sup>2</sup>	P-value <sup>3</sup>
<i>Unadjusted model</i>				
<b>Overall (<math>n = 555</math>)</b>	2.46 (0.83)	<b>0.0034</b>	0.48 (0.28)	0.080
- EA ( $n = 417$ )	2.27 (0.93)	<b>0.015</b>	0.34 (0.30)	0.25
- AA ( $n = 138$ )	1.02 (2.25)	0.65	0.30 (0.80)	0.70
<i>Adjusted model</i> <sup>4</sup>				
<b>Overall (<math>n = 548</math>)</b> <sup>5</sup>	2.36 (0.80)	<b>0.0032</b>	0.25 (0.26)	0.33
- EA ( $n = 413$ )	2.42 (0.87)	<b>0.0058</b>	0.23 (0.28)	0.40
- AA ( $n = 135$ )	1.42 (2.05)	0.49	0.43 (0.74)	0.56

<sup>1</sup>  $\Delta$ Adjusted  $\alpha$ -TOH refers to the change in free-cholesterol-adjusted  $\alpha$ -tocopherol concentration from baseline to year 3.

<sup>2</sup>  $\beta$ , the coefficient of the association of the rs2108622-T allele with the change in  $\alpha$ -tocopherol phenotype.

<sup>3</sup> P-value of the association coefficient. Significant  $P < 0.025$  (Bonferroni correction for testing 2 SNPs) is in bold.

<sup>4</sup> Adjusted for age at baseline, BMI at baseline, ancestry, smoking status, plasma selenium concentration, total vitamin C intake, dietary fiber intake, alcohol intake, baseline  $\alpha$ -tocopherol, baseline  $\gamma$ -tocopherol, and baseline free cholesterol (only in the model with raw  $\alpha$ -tocopherol). 7 participants had missing vitamin C, fiber, and alcohol intake and thus the sample size for the adjusted model was 548.

<sup>5</sup> Total variability explained,  $R^2=18.3\%$  for raw change in  $\alpha$ -TOH (19.2% for change in free-cholesterol-adjusted  $\alpha$ -TOH), and baseline concentrations of  $\alpha$ -TOH,  $\gamma$ -TOH, free cholesterol, ancestry, and rs2108622-T explained 9.2%, 1.7%, 1.3%, 1.7%, and 1.3% of the variability, respectively.

Abbreviations: AA, African ancestry; EA, European ancestry.

**Legends for figures**

**Figure 1.** Flowchart of sample size included in this study

**Figure 2.** Frequency distribution of the change in plasma  $\alpha$ -tocopherol ( $\mu\text{mol/L}$ ) from baseline to year 3 in RAS. The black vertical line denotes the mean change in plasma  $\alpha$ -tocopherol ( $-3.8 \mu\text{mol/L}$ ) in the placebo arm. Vitamin E (vitE) groups include participants in the vitE supplementation only arm and vitE + Selenium supplementation arm. Responders in the vitE groups are defined as having a change in plasma  $\alpha$ -tocopherol greater than  $-3.8 \mu\text{mol/L}$ . The mean and SD of change in plasma  $\alpha$ -tocopherol is shown in each subfigure as well as the proportions of participants who had a change greater than  $-3.8 \mu\text{mol/L}$ .



